Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: 2016

BFM BOURSE – Onxeo : Vers la réparation de l’ADN des cellules tumorales

03/01/201610/08/2019

  Read more on BFM Bourse (in French)  

LES ECHOS – Onxeo veut contrer la réparation de l’ADN des cellules tumorales

03/02/201610/08/2019

  Read the article in Les Echos (in French)  

CANCER RESEARCH NEWS – A new cancer combination

11/16/201610/08/2019

  Read the article in Cancer Research News    

Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference

12/22/201610/03/2019

January 9-12, 2017 in San Francisco, CA  In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC

04/04/201610/03/2019

Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of […]

Passing on Onxeo’s Extraordinary and Ordinary General Meeting

04/06/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment

04/18/201610/03/2019

Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris […]

Onxeo First Quarter 2016 Financial Information and Business Update

04/28/201610/03/2019

Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]

Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco

10/10/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Publication of Shareholder Letter

10/12/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]

Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update

10/25/201610/03/2019

Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]

Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors

10/27/201610/03/2019

Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model Paris (France), Copenhagen (Denmark) – […]

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

11/04/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

11/21/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference

11/28/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

11/29/201610/03/2019

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence […]

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents

02/22/201609/11/2019

Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver […]

Onxeo announces closing of DNA Therapeutics acquisition

03/25/201609/11/2019

Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]

Onxeo Reports 2015 Full-Year Results and Provides Business Update

02/26/201609/11/2019

2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in […]

Publication of 2015 Reference Document

05/02/201609/11/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Announces The Evolution And Reinforcement Of Its Board Of Directors

01/25/201609/10/2019

Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors […]

Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016

03/16/201609/06/2019

Paris (France), Copenhagen (Denmark) –  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo Announces First Outcomes of Livatag® Preclinical Plan

09/12/201609/04/2019

Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced […]

Onxeo to attend upcoming investor conferences and medical meetings

02/17/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan

02/29/201609/04/2019

Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment  Acquisition expands […]

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting

03/16/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo Announces Establishment of U.S. Subsidiary

03/21/201609/04/2019

Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]

Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor

06/02/201609/04/2019

The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq®  Paris […]

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA

06/27/201609/04/2019

Near- and mid term expected milestones  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the […]

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031

07/04/201609/04/2019

Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair […]

Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives

07/07/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology […]

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

07/27/201609/04/2019

Agreement covering seven South American countries Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a […]

Onxeo Reports First-Half 2016 Business Update and Consolidated Financials

07/28/201609/04/2019

– Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics and lead compound AsiDNATM – Important development milestones on existing […]

Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York

09/07/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

09/07/201609/04/2019

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative […]

Onxeo Launches Capital Increase

09/29/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]

Onxeo Raises €12.5 Million through Capital Increase with US and European Investors

09/30/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in […]

Onxeo Announces Its Financial Calendar for 2017

12/07/201609/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

12/08/201609/04/2019

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class […]

Onxeo to Attend Two French Investor Conferences in January

12/22/201609/04/2019

Oddo Investor Forum, January 5-6, 2017 in Lyon Invest Securities BioMed Event, January 26, 2017 in Paris  Paris (France), Copenhagen […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress